Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab to prevent radiation retinopathy after Iodine-125 plaque therapy for posterior uveal melanoma
2008-008720-33Phase 3Completed
- Sponsor
- Cliniques universitaires Saint-Luc
- Start
- May 2009
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ranibizumab in Radiation chorioretinopathy, sponsored by Cliniques universitaires Saint-Luc. Primary endpoint: Change in central retinal thickness from baseline to 12 months. Started May 2009; status: completed.
02
Drugs
ranibizumab
03
Conditions
Radiation chorioretinopathy
Beyond the preview
Go deeper on 2008-008720-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008720-33.